Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalpiciclib + Exemestane + Goserelin Neoadjuvant Therapy in Premenopausal Breast Cancer
NCT06009627Phase 3Completed
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Apr 2023
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of dalpiciclib in breast cancer, sponsored by Tianjin Medical University Cancer Institute and Hospital. Started Apr 2023; status: completed.
02
Drugs
dalpiciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06009627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06009627.